At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 531–540 of 620 results.
-
The purpose of this study is to assess the effectiveness of adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy for patients who have a recurrence of their prostate cancer after surgery (prostatectomy). Specifically, there must have been cancer originally found in the lymph nodes at the time of surgery for patients to be eligible for this study. The treatment being evaluated is a "salvage therapy" for recurrent prostate cancer. Patients will be randomly assigned to receive hormone therapy and radiation therapy after prostate cancer surgery with or without apalutamide, abiraterone acetate, and prednisone.
-
Researchers are assessing the combination of BNT326 and BNT327 in people with advanced lung cancer that has spread. The people in this study have non-small cell lung cancer (NSCLC) that came back or keeps growing after treatment.
-
Researchers want to find the best dose of HC-7366 to use alone and with belzutifan in people with kidney cancer. The people in this study have advanced renal cell carcinoma (kidney cancer) that keeps growing after prior treatments. The cancer either cannot be removed (is inoperable) or has metastasized (spread).
-
In this study, researchers want to see if enzalutamide, alone or with mifepristone, works well against advanced breast cancer. The people in this study have either triple-negative breast cancer (TNBC) or cancer that is low in estrogen receptors (ER). Receptors are docking sites on cancer cells for hormones or other proteins. TNBC is breast cancer that is not fueled by estrogen or progesterone and does not make a protein called HER2. The people in this study also have cancer cells that have receptors for proteins called androgens (AR-positive cancers).
-
Researchers want to see if bulumtatug fuvedotin works well against breast cancer. The people in this study have triple-negative breast cancer (TNBC) that came back or spread after treatment.
-
Researchers want to see how well ulixertinib works in people with histiocytic neoplasms. Histiocytic neoplasms are rare diseases in which too many white blood cells called histiocytes build up in tissues and organs. This can cause damage to tissue or tumor(s) to form. The tumor(s) may be benign (not cancer) or malignant (cancer). There are different types of histiocytic neoplasms, including:
-
Researchers are seeking the best dose of CLSP-1025 to use in people with advanced solid tumors. The people in this study have cancers with a mutation (change) in the p53 gene called R175H. They are also positive for a specific human leukocyte antigen (HLA type A*0201). HLA is a protein on cells that plays an important role in the immune response to foreign substances.
-
Researchers want to see if the combination of epcoritamab and ibrutinib is a safe treatment for people with central nervous system lymphoma (CNSL) that keeps growing or came back after treatment.
-
This study is assessing a new treatment approach for people with oligometastatic breast cancer. This means their cancer has spread to a small number of other parts of the body. Their cancers have high levels of the HER2 protein, which promotes breast cancer growth. In addition, they started drug therapy for their cancer and it has not gotten worse in the last 3-12 months.
-
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.